Compare Appian Corp (APPN) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Appian Corp vs Gilead Sciences, Inc. — how do they compare? Appian Corp trades at $35.5 (market cap $2.54B), while Gilead Sciences, Inc. trades at $135.28 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 66.3× Appian Corp's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Appian Corp pays none. Which is the better fit depends on your goals.
| APPN | GILD | |
|---|---|---|
Market Cap | $2.54B | $168.35B |
Sector | Technology | Health |
52-Week High | $45.64 | $155.80 |
52-Week Low | $18.72 | $110.56 |
Enterprise Value | $2.67B | $191.42B |
Dividend Yield | — | 2.42% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
